Reported Sunday, MacroGenics Presents Efficacy And Safety Data For Vobra Duo In Phase 2 TAMARACK Study At ESMO 2024
Benzinga Newsdesk 2 years ago
News
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR Patients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of
- Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR
- Patients remained on vobra duo through a median of 6 doses (ranging up to 12), representing an extension of treatment duration as compared to Phase 1 mCRPC dose expansion cohort
- Company expects to have mature median rPFS no later than early 2025
- MacroGenics to host an investor call to review key data presented at ESMO and provide a general corporate update on Monday, September 16, 2024, at 8:00 a.m. ET